# Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

> **NCT02621333** · PHASE2 · TERMINATED · sponsor: **Henan Cancer Hospital** · enrollment: 280 (actual)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **BIOLOGICAL:** CIK
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT02621333
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 280 (ACTUAL)
- **Why stopped:** As there are so many clinical trials in progress and the number of patients enrolled limited.
- **Last updated:** 2021-05-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02621333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02621333, "Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02621333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*